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Clinical Relevance  
Fish oil, rich in n-3 polyunsaturated fatty acids (PUFAs), is a potential dietary 
supplement to lower prostate cancer risk. The mechanism of action of fish oil on 
prostate tumor growth inhibition remains largely unknown. While the n-3 fatty acids may 
exert important anticancer effects, the effects of other types of fatty acids such as oleic 
acid, a n-9 fatty acid and the main fatty acid in olive oil, are much less known. Roles of 
these PUFAs in prostate cancer have been investigated previously, however, conflicting 
results and the limitations in the experimental design make it clear that additional work 
needs to be conducted, especially at the cellular level, to better understand the 
pathways by which FO help reduce prostate cancer risk. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abstract 
Purpose: The aim of this study is to investigate the role of n-3 and n-9 fatty acids in 
crucial processes involved in prostate cancer cell growth through a large-scale 
proteomic analysis.  
Experimental design: We used a label-free protein quantification method to profile 
global protein expression of fish oil and oleic acid treated PCa cells and validated a 
panel of differentially expressed proteins by either Western blot or multiple reaction 
monitoring. Bioinformatic analysis was also performed to uncover the pathways involved 
in fatty acid metabolism. 
Results: Fish oil, not oleic acid, suppresses prostate cancer cell viability. Assessment 
of fatty acid synthesis pathway activity also shows that oleic acid is a more potent 
inhibitor than fish oil on de novo fatty acid synthesis. Although fatty acid synthase 
activity decreases with fish oil treatment, the inhibition of its activity occurs over time 
while reduction in viability occurs within 24 hours. Bioinformatic analysis revealed the 
pathways altered by these fatty acid treatments. 
Conclusions and clinical relevance: This study suggests that suppression of cell 
viability by fish oil is independent of fatty acid synthase and fish oil regulates prostate 
cancer cells through activation of other pathways depending upon length of exposure to 
fish oil.  
 
 
 
 
1 Introduction 
Prostate cancer (PCa) is the second most common cancer in men [1]. The risk of 
PCa is currently one in six men (16.7%) and the overall risk of death due to metastatic 
PCa is about 2.8% with the disease progressing slowly to advanced stage [2-4]. To date 
little is known about the etiological factors associated with PCa development and 
progression. There is increasing evidence suggesting that diet and lifestyle play a 
crucial role in PCa tumorigenesis [5, 6]. However, a common consensus on which 
nutrients may be beneficial and which could be harmful is lacking, and this is further 
complicated by the contradictory reports about the role of different dietary components 
and nutrients on PCa prevention and progression [7-10].  
Although two recent studies failed to support  the role of fish oil (FO), which is rich in 
n-3 polyunsaturated fatty acids (PUFAs), especially docosahexaenoic acid (DHA, C22:6, 
n-3) and eicosapentaenoic acid (EPA, C20:5, n-3), in protecting men against developing 
PCa [10, 11], it has long been viewed as a beneficial dietary supplement to lower the 
risk of PCa through suppressing PCa cell growth and inducing cell apoptosis, 
strengthening the effect of anti-tumor drug treatments to PCa cells	[12-16]. These 
conflicting results and the limitations in the design of previous studies, make it clear that 
additional work needs to be conducted, especially at the cellular level, to better 
understand the pathways by which FO help reduce PCa risk.  
Roles of other PUFAs in PCa have also been studied previously [17-20]. For 
example, an epidemiological study suggests that high ratio of n-6/n-3 PUFAs uptake is 
positively associated with PCa risk [17]. Besides n-3 and n-6 FAs, other fatty acids (FAs) 
such as oleic acids (OA, C18:1, n-9), an n-9 monosaturated FA component, may also 
play important roles in reducing cancer risk. Unlike n-3 PUFAs, which are derived from 
limited sources (flaxseed, certain fish), n-9 fatty acids (such as OA) are one of the 
dominant components in most daily cooking oil. Results from studies investigating OA 
and cancer, however, are controversial. Some studies indicate OA has inhibitory effects 
on PCa cells	[18], while others observed a higher OA/stearic ratio in untreated and more 
advanced PCa patients [19, 20]. However, whether the high level of OA/stearic ratio is 
due to more endogenous OA production, dietary OA consumption, or the decrease level 
of stearic acid remains to be investigated. In the present study, we selected OA, a 
commonly consumed fatty acid, to be used in comparison with FO to identify the 
pathways activated or suppressed in PCa cells, specifically by FO and/or by OA. One of 
the downstream targets of dietary FAs is fatty acid synthase (FASN) [21], which is 
associated with development of multiple cancers and is currently being pursued as a 
therapeutic target [22]. Dietary PUFAs have been shown to suppress de novo synthesis 
of fatty acids via FASN through inhibition of the sterol regulatory binding protein 1c 
(SREBP-1c) [23, 24]. Prostate tumor cells show markedly higher FASN expression 
compared to adjacent tissues [25, 26]. FASN regulates a series of genes and pathways	
[27], some of which play critical roles in cell viability and its inhibitors have been 
reported to have anti-cancer effects	[26, 28, 29]. N-3 PUFAs also modulate other 
molecules in PCa. One study suggests androgen receptor (AR) protein expression may 
be down-regulated by DHA treatment	[30]. N-3 PUFAs also regulate enzymes involved 
in n-3 PUFA processing, for instance, cyclooxygenase 2 (COX2)	[31]. 
To date the mechanism of FO’s effects on PCa remains unknown. There is 
increasing evidence suggesting that FO may have multiple targets and thus its 
regulation may also be multi-level. This makes global proteome comparison an 
attractive approach. This study evaluated FO and OA’s effects on PCa cell viability and 
FASN activity and sought to answer how the protein profiles are being regulated by FO 
or OA in a longitudinal manner with an LC-MS/MS method. 
 
2 Materials and methods 
2.1 Cell line 
The PCa cell line, PC3 (ATCC), was grown in RPMI-160 medium (HyClone, Logan, 
UT, USA) supplemented with 10% FBS (Sigma-Aldrich, St. Louis, MO, USA), 100 U/ml 
penicillin and 100 g/ml streptomycin (Lonza, Walkersville, MD, USA) in 37°C with 5% 
CO2. For the androgen receptor positive PCa cell line, LAPC4, IMDM medium 
(HyClone, Logan, UT, USA) was used.   
2.2 FA treatment，chloroquine treatment and conditioned media collection 
FO and OA were purchased from KD Pharma Bexbach GmbH (Bexbach, Germany). 
FO capsules contained 90% n-3 fatty acid ethyl ester (40% EPA, 40% DHA and 10% 
other n-3 PUFAs). OA capsule contained 90% oleic acid ethyl ester. 100 mM stock was 
made by dissolving fatty acids (FAs) in ethanol. When treating the cells, FAs-ethanol 
stock solution was mixed into complete medium at a 1:1000 ratio to a final concentration 
of 100 M, while 0.1% ethanol was used in controls. For day-6 treatment samples, the 
medium was changed four days after the treatment with a fresh medium containing FAs. 
In autophagy suppression assay, chloroquine diphosphate salt (Sigma-Aldrich, St. Louis, 
MO, USA) was diluted to 8 M in medium. To harvest conditioned medium (CM), the 
growth medium was replace with serum-free medium, CM was harvested 24 hrs later 
and cell debris was removed with centrifugation at 1,500 rpm. CM volume was 
normalized based on cell count with fresh serum-free medium to reach a same 
volume/cell number ratio among different treatments.  
2.3 Clonogenic cell survival assay 
Cells were seeded in 6-well plates (1,000 PC3 cells or 3,000 LAPC4 cells per well, 
respectively) and grown in complete medium with different FA treatments. Colonies 
formed at approximately 1 week for PC3 cells and 1.5 weeks for LAPC4 cells. Colonies 
were fixed and stained with crystal violet, washed and counted. 
2.4 Cell proliferation assay 
Cells were seeded in 96-well plates (1,000 PC3 cells or 6,700 LAPC4 cells per well, 
respectively) and grown in complete medium with different FA treatments.  The MTT (3-
[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide) assay was carried out by 
incubating cells with MTT (Sigma-Aldrich, St. Louis, MO, USA) for 4 hrs. DMSO was 
used to dissolve the formazan. Absorbance was measured at 570 nm.  
2.5 Western blot 
Cell pellets were lysed by NP-40 lysis buffer supplemented with 1% protease 
inhibitor (Thermo-Fisher Scientific, Waltham, MA) and phosphatase inhibitor (Sigma-
Aldrich, St. Louis, MO, USA). Laemmli buffer (Bio-Rad, Hercules, CA, USA) containing 
5% 2-mercaptoethonal (Fisher Scientific, Pittsburgh, PA, USA) was added to cell lysate 
supernatant and the mixtures were boiled to denature. Proteins were separated by 
SDS-PAGE gel then transferred to PVDF membrane (Bio-Rad, Hercules, CA, USA). 
Blocking was done in 5% BSA (Roche, Indianapolis, IN, USA). PVDF membrane was 
incubated with primary antibodies anti-MSMP (Abnova, Walnut, CA, USA), anti-
sequestosome-1 (Novus Biologicals, Littleton, CO, USA), anti-beta-actin (Fisher 
Scientific, Pittsburgh, PA, USA) and secondary antibodies (Santa Cruz Biotechnology, 
Santa Cruz, CA, USA) and Cell Signaling Technology (Danvers, MA, USA) sequentially. 
To detect LC3 I/II, cells were lysed by lysis buffer (1% Triton-X100, 150 mM NaCl, 50 
mM Tris pH7.6), LC3 antibody were purchase from Thermo-Fisher Scientific (Waltham, 
MA, USA). Bands were detected by ECL™ Western Blotting Detection Reagents 
(Amersham™, GE Healthcare, Piscataway, NJ, USA).  Quantification was carried out 
using ImageJ, an open source image processing program. 
2.6 FA synthesis measurement 
Cells were incubated with complete culture medium with 1 Ci/ml 1,2-14C-acetic acid 
sodium salt (PerkinElmer, Waltham, MA) was added to complete medium and cells 
were incubated for 2 hrs. The medium was discarded. For lipid extraction, 0.9 ml 
chloroform/methanol (2:1, v/v) mixture and 0.7 ml 4 mM MgCl2 were added to the cells. 
The mixture was vortexed thoroughly and centrifuged at 10,000 rpm. The upper 
aqueous layer was removed and the lipid was maintained in bottom layer which is the 
chloroform fraction. Extraction was repeated for 3 times. Every sample was air dried in 
fume hood, then re-dissolved in 200 µl chloroform and finally transferred to 10 ml 
scintillation fluid Ultima Gold™ F (PerkinElmer). Disintegration Per Minute (DPM) value 
was measured by TRI-CARB 2100TR liquid scintillation analyzer (Packard Instrument 
Company, Kennesaw, GA). 
2.7 Real-time PCR 
Cells were harvested and RNA extraction was carried out using RNeasy Plus Mini 
Kit (Qiagen, Valencia, CA, USA). Reverse transcription was performed using 
QuantiTect Reverse Transcription kit (Qiagen). Realtime PCR was performed on 
QuantStudio 12K Flex (Applied Biosystems, Foster City, CA, USA) and the protocol was 
designed  according to Taqman Gene Expression Assay (Applied Biosystems, Foster 
City, CA, USA). Sequestosome-1 (SQSTM1) was labeled with reporter dye FAM. 
Glucuronidase β (GUSB), which serves as internal standard was labeled with reporter 
dye VIC. Realtime PCR primers and probes targeting SQSTM1 (assay ID 
Hs01061917_g1), GUSB (assay ID: Hs00939627_m1), as well as Mastermix (the 
reaction solution), were designed and purchased from Applied Biosystems.  
2.8 Mass spectrometry 
For global unbiased proteomic analysis, cell pellets were lysed in 8 M urea and 10 
mM dithiothreitol (DTT) and then sonicated on ice. Equal amount of chicken lysozyme 
was spiked into each sample at a final concentration of 0.5% (w/w), serving as a quality 
assurance (QA)/quality control (QC) reference. Reduction/alkylation of cysteine 
residues was done by incubating the cell extracts with acetonitrile 
(ACN)/iodoethanol/triethylphosphine (195:4:1, v/v/v) mixture. Samples were dried in a 
speed vacuum concentrator (Genevac, NY, USA) and resuspended in 310 µl of 100 mM 
ammonium bicarbonate, followed by overnight trypsin (Worthington, Lakewood, NJ) 
digestion (trypsin:protein=1:25). Desalting was carried out by repeating ACN-H2O with 
0.1% formic acid wash in Silica C18 MacroSpin Column (The Nest Group, 
Southborough, MA, USA). The resulting peptides were eluted by 80% ACN in last step 
and speed-vac dried. Samples were resuspended in 5% ACN in water with 0.1% formic 
acid and filtered through Ultrafree-MC Centrifugal filters (EMD Millipore, Billerica, MA). 
Peptides were eluted with a linear gradient from 5% to 80% ACN developed over 120 
min at a flow rate of 50 l/min, and effluent was electro-sprayed into the LTQ Orbitrap 
Velos Pro mass spectrometer (Thermo-Fisher Scientific, Waltham, MA, USA). Two 
injections of each sample were carried out randomly. X!tandem algorithms were applied 
to search the acquired data against UniProt human database (released in April 2013). 
Peptides and proteins were validated using PeptideProphet and ProteinProphet in the 
Trans-Proteomics Pipeline (TPP, v.4.6). All the proteins listed in this study have protein 
probability >99.8% and peptide probability >80%. Label-free quantification was carried 
out using IdentiQuantXLTM [32].   
2.9 MRM-based validation 
 Sample preparation, including cell lysis, reduction/alkylation and digestion was 
carried out the same way as that in proteomic discovery. Mass spectrometric analyses 
were performed on an AB/SCIEX 4000 Qtrap mass spectrometer (Sciex, Framingham, 
MA, USA) interfaced with a Dionex U-3000 UHPLC system (Thermo-Fisher Scientific, 
Waltham, MA, USA). Peptides were injected on an ODS-100V C18 column (1.0mm x 
150mm, Tosoh Biosciences, South San Francisco, CA, USA) and eluted with a linear 
gradient from 5 to 80% acetonitrile over 32 min at a flow rate of 50 µl/min. The 
parameters were as follows: curtain gas of 40.0 psi, collision gas of 7 psi, ion spray 
voltage of 5500 V, temperature set at 500 oC, ion source gas 1 of 50.0 psi, ion source 
gas 2 of 40.0 psi. Entrance potential is set on 10.0 V; collision cell exit potential is 12.0 
V. Data acquisition was carried out using the AB/SCIEX Analyst® software. For MRM 
development, the Skyline software was first used to generate candidate peptides and 
theoretical transitions for each peptide. PC3 cell lysate was tested to select the best 
experimental peptide and transitions, which could be stably detected and also had high 
peak intensity. One specific transition was monitored for each target peptide, which 
represents one specific protein. Each monitored transition was confirmed by spiking in 
varied concentration of the corresponding synthetic peptides. For FSCN1, a transition 
for target peptide 23YLTAEAFGFK32 was monitored: m/z 573.8 (M+2H+) → m/z 870.4. 
For CANX, a transition for target peptide 78GTLSGWILSK87 was monitored: m/z 531.3 
(M+2H+) → m/z 790.4. For MSMP, a transition for target peptide 52YFTLGESWLR61 was 
monitored: m/z 636.3 (M+2H+) → m/z 747.4. For SCP2, a transition for target peptide 
48IGGIFAFK55 was monitored: m/z 426.8 (M+2H+) → m/z 739.4.  A transition for chicken 
lysozyme, which serves as external standard, target peptide 40GYSLGNWVCAAK61 was 
monitored: m/z 656.8 (M+2H+) → m/z 892.4. We also monitored a transition for RPL6, 
which serves as the internal standard, target peptide: 211HLTDAYFK218, m/z 497.8 
(M+2H+) → m/z 744.4. Declustering potential (DP) and collision energy (CE) were 
optimized for each peptide. Scan time for each peptide was 120 msec and total scan 
time was 0.875 sec. Quantification of target peptide was performed using Skyline 
software to calculate area under curve (AUC) of extracted ion chromatograms. 
 
3 RESULTS 
The aim of this study was to better understand the pathways involved in FO 
inhibition of PCa cell viability and to further investigate FO and OA’s effects in global 
protein expression. We compared global protein expression profiles of PC3 cells treated 
with FO and OA at two different time points. Protein expression data presented here 
clearly demonstrate that FA-mediated molecular changes are not directly linked to 
FASN activity and the function of FAs may likely be mediated through multiple targets.   
3.1 FO, not OA inhibits PCa cell growth 
A MTT cell proliferation assay was performed to assess cell viability upon PUFA 
treatment. Shown in Fig. 1A, FO, not OA, suppresses cell viability. A significant 
difference in cell growth (FO=74.8%C, p=0.0105) was observed after 24 hours in the 
FO treated cells but not in OA group (OA=101.4%C, p=0.5493). This observation was 
confirmed by clonogenic assays, in which colony density was significantly lower with FO 
treatment (Fig. 1B). Clonogenic cell survival assays were also performed on androgen 
receptor (AR) positive LAPC4 cells (data not shown). FO treatment demonstrated 
significant inhibition of colony formation (p<0.05) with no LAPC4 colonies observed in 
FO treated group after 1.5 weeks. Again, the OA group showed no significant change 
as compared to control group (p=0.2842). During colony formation, vacuoles were 
observed in the FO treated cells, which remained single cells and stopped proliferating 
(Fig. 1C). 
3.2 Both FO and OA inhibit FA synthesis and OA is a more potent inhibitor than 
FO 
De novo FA synthesis was measured in the FO and OA treated groups after three 
days and six days treatment. At day three there was no change in fatty acid synthesis 
with fish oil treatment (Fig. 2A), while a 30.97% (p=0.0001) suppression was observed 
in the OA group. After six days of treatment, a significant FA synthesis suppression was 
observed in both FO (27.11%, p<0.05) and OA (49.21%, p<0.0001) groups (Fig. 2B). 
Additionally, OA’s FA synthesis level was lower than FO (OA=69.7%FO, p=0.0301), 
which suggests that OA is a more potent FA synthesis inhibitor than FO. This 
observation also implicates that the viability inhibition effect of FO on PC3 cells may not 
be directly linked to FA synthesis. 
3.3 The differential proteome profile in prostate cancer cells treated with FO or 
OA 
LC-MS-based label-free protein quantification was performed to investigate the 
longitudinal regulation of FO and OA on PCa cells. PC3 cells were plated at ~170,000 
cells/plate on 100-mm plates with the complete medium with 0.1% ethanol, 100 M FO, 
or 100 M OA, respectively. Cells were harvested on day 1 and day 6 after treatment for 
MS analysis. A total of 1,478 proteins were identified with protein probability >99.8% 
and peptide probability >80%. Protein and peptide probabilities were produced through 
calculation by TPP. Random sequences were set up serving as decoy sequences. A 
protein identification probability >99.8% corresponds to a FDR of <1%, which is a 
commonly used cutoff in the proteomics field.   
Protein expression comparison was conducted based on treatment conditions 
(control, FO, and OA) and time-course (day-1 and day-6). Three hundred and twelve 
proteins were positively identified based on p-values less than 0.05. As indicated in the 
Supplementary Table S1, majority of the technical variations are under 10% with a few 
outliers based on the internal control (chicken lysozyme) data and the overall %CV is 
below 13% (Supplementary Table S1). This is what we expected from this type of global 
protein profiling experiment with the platform we applied. The data was further filtered 
by FDR-adjusted p value (q value cut off=0.05) and the expression levels of 127 
proteins were significantly changed upon treatment (Supplementary Table S2). Principal 
component analysis (PCA) was performed on this 127-protein dataset that consisted of 
6 treatment groups with 5 replicates in each group. Prolonged FO treated group (FO-6 
day) was a distinct group indicated by the red circle, separated from the other 
treatments (Fig.3A). The blue and yellow circles indicate there were fewer protein 
changes among treatments in day-1 and between control and OA group in day-6. By 
comparing each FO or OA group to its same-day corresponding control group, 73 
proteins showed significant changes (p≤0.05). Log2(Ratio<FO/C>) and  
Log2(Ratio<OA/C>) values of protein entries were clustered by one minus Pearson 
Correlation (Gene E online analysis platform, 
http://www.broadinstitute.org/cancer/software/GENE-E/). Three major clusters were 
generated (shown in Fig.3B). Cluster A contained 7 proteins (encoded by 6 genes) 
(Table 1), including SCP2 and acyl-coenzyme A oxidase which participate in fatty acid 
transport and metabolism [33, 34]; coactosin-like protein is reported to be involved in 
PUFA metabolism [35]. Cluster B showed that five of the six proteins (encoded by 4 
genes) were significantly elevated in the FO group one day after treatment, and protein 
expression levels were higher than the OA group. Among these proteins, 
sequestosome-1 (SQSTM1) and heat shock 70 kDa protein 1A/1B (HSPA1A) were 
identified and have roles in the autophagy process [36, 37]. In cluster C, which 
consisted of 60 protein entries, no significant changes were observed in FO and OA 
groups in the first day of treatment. However, on day-6, FO-treated and OA-treated 
groups showed divergent protein expression changes. In the FO-treated group, 53 out 
of 60 proteins showed a significant decrease in expression while in the OA-treated 
group, the majority of differentially regulated proteins were elevated and eight of the 
changes were significant. Ingenuity® pathway analysis (IPA) indicated that cell 
movement, growth and proliferation, cell development, cell death/survival, and 
carbohydrate metabolism were the most significant molecular and cellular functions 
involved (Table 2), while glycolysis and gluconeogenesis were the top canonical 
pathways. Four enzymes from cluster C: phosphoglycerate kinase 1 (PGK1), 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH), pyruvate kinase isozymes 
M1/M2 (PKM) and its isoform M1 (PK) and glucose-6-phosphate isomerase (GPI) were 
all significantly decreased in expression in FO-6-day treated group, but have little 
change in the OA-6-day treated group (Fig. 4).  
In combination with IPA, the proteins with significant expression changes were 
selected based on the following criteria: 1) protein probability >99.8%; 2) two or more 
unique peptide sequences identified with high confidence; 3) within every group, 
ANOVA p-value  0.05, q-value  0.05; 4) multiple comparison test p-value  5/ Ntotal 
tests-; 5) protein frequency (occurrence in all injections) >50%; 6) association with cancer, 
prostate, or lipid processing; 7) absolute fold change >1.3. Under these stringent criteria, 
we identified only one differentially regulated protein, sequestosome-1 (SQSTM-1), in 
the day-1 treatment group. SQSTM-1 was elevated (1.7-1.8 fold) in the FO group 
compared to control and OA group. In the 6-day treatment comparison, the expression 
levels of 4 proteins were significantly altered as compared to the controls (Table 3).  
3.4 Key differentially expressed protein validation 
Both Western blot and MRM-based methods were used for validation studies to 
confirm the differential protein expression observed in the global discovery study. Since 
the majority of these proteins were in the day-6 treatment group, we used an 
independent set of day-6 samples for validation studies. In MRM, for each selected 
protein, one unique peptide and one pair of precursor and product ions (MRM 
transitions) were selected. Relative quantity and specificity of these MRM 
peptides/transitions are illustrated in Supplementary Figures S1, S2, and S3. Synthetic 
standard peptides were first tested to confirm the transition ion pairs derived from 
Skyline. Results showed that among the 4 proteins changed in the day-6 treatment 
group, prostate-associated microseminoprotein (MSMP) was found significantly 
decreased when the FO treatment group was compared to control (63.3% lower 
expression in the FO group, p=0.0242). Down-regulation of MSMP in the OA treated 
group was not significant (28.4% lower expression, p= 0.3474), (Fig. 5A). Since MSMP 
is also a secreted protein, we tested expression in conditioned medium (CM) of PC3 cell 
grown in the presence of FO, OA or vehicle. Western blot results show that secreted 
MSMP in CM appears as a single band around 16kD. FO treated PC3 cells secreted 
less MSMP compared to control (p=0.0096) or OA group (p=0.029) (Fig. 6F & 6G). 
The other protein, sterol carrier protein 2 (SCP2), was also found to be significantly 
up-regulated in the FO treated group compared to control (47.1% over-expressed in FO 
group, p=0.001), or OA (27.8%FO, p= 0.0113) (Fig. 5B). However, unlike the global 
proteome results, there was no significant change between OA and C. No significant 
changes were observed in spiked-in chicken lysozyme and RPL6, which served as 
QA/QC samples (constant amount among three groups observed) (Fig. 5C & 5D). 
Sequestosome 1 (SQSTM1), a protein involved in autophagy, was found to be over-
expressed in FO group one day after the treatment in our global proteomic study. 
Western blot results were consistent with the LC/MS results that demonstrated 
SQSTM1 levels in the FO group were 2.1-fold higher than that in the control group 
(p=0.042) (Fig. 6A & 6B). Although the proteomic analysis also showed a higher level 
of expression in FO group when FO and OA groups were compared (fold-change=2.35), 
the change, however, was not statistically significant (p=0.0867) based on our p=0.05 
cutoff. There was no significant difference between OA and control. Real-time PCR 
results showed that at the transcriptional level, mRNA expression of SQSTM1 in FO 
treated group was higher than both control (fold-change=2.16, p=0.003) and OA treated 
group (fold-change=2.26, p=0.003) (Fig. 6C). To further investigate the function of 
autophagy, autophagy inhibitor chloroquine (CQ) was applied to cells with different FA 
treatment, and LC3 I/II levels were measured by Western blot. The results indicated that, 
under the condition of autophagy suppression induced by CQ, LC3 II levels 
accumulated significantly (two-way ANOVA, p=0.0005) while LC3 I levels were not 
affected. However, no significant LC3 II changes were observed among FA treatment 
groups (two-way ANOVA, p=0.7853) (Fig. 6D, 6E), suggesting that autophagy may not 
be significantly inhibited under this experimental condition. 
 
4 DISCUSSION 
Saturated fatty acids, OA, and n-6 PUFA are main components of daily cooking oil, 
including corn, peanut or sunflower seed oil. Except for flaxseed oil (alpha-linolenic acid, 
ALA) and some fish (DHA and EPA), n-3 PUFA, one of the essential FAs, exist as a 
very small portion of dietary oil intake. Proteomic studies of this sort have been carried 
out to investigate the global protein level change under different dietary FA consumption. 
However, most of these studies used two-dimensional gel electrophoresis approaches 
with the study objectives varying from insulin resistance to colon inflammation [38-44]. 
Large-scale proteomic studies on dietary fish oil effect on PCa using the label-free 
protein quantification method have not yet been reported.  
In this study, we investigated the different molecular pathways of OA and FO action 
in PCa cells. Previous investigations of n-3 PUFAs and PCa have pointed to some of 
the potential mechanisms of FO on PCa growth inhibition. One study detected down-
regulated AR protein expression in LNCaP cells after 10 weeks continuous 20 M DHA 
treatment [30], while another study did not detect a AR protein change in LNCaP cells 
treated by DHA at concentrations as high as 180 M for 24 to 36 hrs [14], suggesting 
differential regulatory changes over time may have occurred during the treatment 
periods. One point worth noting is that the concentration of the fatty acids used for this 
study is based on our preliminary experiments and other reported studies [13, 45, 46]. 
At 100 M, FASN activity is significantly reduced by OA while cell viability remains 
unaffected. However, in vivo human exposure to this concentration of FAs may never 
reach 100 M due to its poor water solubility and lipid intake limitation. Thus the actual 
exposure of the cells to FAs may be much lower than the calculated 100 M 
concentration. 
Our results suggest that only FO, not OA, suppresses PC3 cell viability, and this 
inhibition occurred as early as one day after the treatment. Hierarchy analysis of global 
proteomic data generated a group of proteins in which the majority of proteins were 
increased after 24-hr FO treatment. Specifically, both sequestosome-1 (SQSTM1), heat 
shock 70 kDa proteins A1A/A1B are connected to autophagy [36, 37] and both were 
significantly elevated one day after FO treatment but with no change in the OA treated 
group. This result indicates FO, not OA, triggers rapid stress-responding reactions, 
which may explain the early event of viability inhibition. The elevated expression of 
SQSTM1, an autophagy associated protein, was also validated by Western Blot (Fig. 
6A & 6B). Tumor cells activate autophagy in response to cellular stress and/or 
increased metabolic demands related to rapid cell proliferation.	In the dynamic process 
of autophagy, SQSTM1 is required for the degradation of polyubiquitinated substrates, 
and SQSTM1 itself is also degraded during this process. The accumulating SQSTM1 
level implicates a possible inhibition of autophagy, which in turn causes the 
accumulation of SQSTM1 that should be otherwise degraded in a normal autophagy 
process, suppressing the growth of the tumor cells. Consistent with our result, one study 
also found elevated SQSTM1 12-hr after the treatment of EPA in promyelocytic cells 
[47]. Conversely, Shin et al. showed that autophagy, in this case acting as a tumor 
suppressor, was activated by DHA and played a critical role in apoptosis of PC3 cells 
induced by DHA [48]. However, in investigating the cause of SQSTM1 elevation under 
FO treatment, we found this increased protein expression was most likely regulated by 
transcriptional mechanism rather than reduced post-translational degradation, 
implicating other transcription regulator(s) may be involved. It has been previously 
reported that oxidation stress can induce SQSTM1 at the transcriptional level, and 
SQSTM1 triggers antioxidant effects [49]. Since FO was found to induce oxidation 
stress and cytotoxicity [50], we suggest that the observed increase of SQSTM1 might 
take place at the stage when cells are starting to respond to oxidation stress.  
Our study suggests that although OA suppressed FA synthesis rate to near 50% on 
day 6, FASN protein level showed no significant change in the OA group compared to 
control. One study in C6 glioma cells suggested OA was a stronger inhibitor than n-3 
PUFA and other FAs in FA synthesis [51]. Consistent with their result and another study 
in 1999 [24], we found no protein level changes in FASN expression. Interestingly, they 
discovered that OA down-regulated the expression of another key enzyme in FA 
synthesis, acetyl-coenzyme A carboxylase, which is involved in the formation of 
malonyl-CoA. In contrast, FASN expression levels in FO treated group are decreased 
compared to OA group (t-test, p=0.05, multiple comparison test p=0.1), indicating 
additional transcriptional level modulation of FASN was triggered by FO.  
Our quantitative global proteomic study also revealed that a group of 
glycolysis/gluconeogenesis enzymes were changed in FO treated cells and four of the 
enzymes were significantly down-regulated in the 6-day treatment group. Although most 
of the decreased enzymes are shared by both glycolysis and gluconeogenesis, PKM 
specifically catalyzes a rate-limiting step in glycolysis. In PCa, glucose is not a major 
bioenergy source as in many other cancer types [52], therefore rendering FDG-PET 
imaging ineffective for PCa tumor imaging [53]. However, a study based on NIH dbEST 
database showed PCa tissue has 9 out of 10 glycolysis genes overexpressed compared 
to normal tissue [54]. Additionally, some glycolytic enzymes, PKM and PGAM1, are 
expressed differently between PCa and normal tissue by isoform or post-translational 
modification (PTM) level [55]. PCa cell sensitivity to stress is enhanced when glycolysis 
is suppressed [56]. This suggests glycolysis still plays a role in PCa even though the 
glucose uptake is low. Expression of hepatic pyruvate kinase [57] and glucose-6-
phosphate dehydrogenase [58] were also reportedly blocked by n-6 or n-3 PUFAs. One 
of the possible mechanisms is through prevention of chREBP translocating to nuclei 
[59]. In the context of cancer cells, the inhibition may be mediated by liver kinase B1 
(LKB) [60]. Effects of PUFAs on glycolysis are tissue specific so that in skeletal muscle 
cells, the process is reversed [45]. Our study indicates FO may suppress glycolysis by 
decreased multiple enzyme expression, suggesting that in the PC3 cell line, de novo FA 
synthesis decreases in later time points may be due to the lower pyruvate supplied by 
glycolysis. To the contrary, prolonged OA treatment does not suppress glycolytic 
enzyme expression and we therefore conclude that FO and OA may inhibit FA 
synthesis through different pathways, which are dependent or independent of glycolysis 
down-regulation, respectively. 
Besides involvement of glycolytic enzymes, additional potential targets of FO were 
investigated and validated in independent sets of samples. Among the five candidate 
proteins in the 6-day treatment arm, the increase of SCP2 and decrease of MSMP was 
validated by MRM. In the global study, SCP2 was elevated in both FO and OA, with the 
FO group demonstrating significantly higher than OA and control. This result was 
confirmed by Western Blot analysis, although the SCP2 increase in OA group was not 
significant. Functionally it is expected that this lipid carrier protein expression would 
increase when exogenous FAs are added to the medium. The other protein, consistent 
in validation experiments, MSMP, is a highly conserved protein and belongs to beta-
microseminoprotein family and its expression was observed in both benign and tumor 
tissues although immunohistochemical analysis demonstrated that tumor MSMP 
expression is different from the pattern in benign tissue [61]. As a recently identified 
protein, MSMP has not been well studied. One report suggested MSMP’s role in 
inflammation as a ligand binding to CC chemokine receptor 2B (CCR2B) and acts as a 
chemoattractant, which induces the migration of peripheral blood monocytes (PBM) and 
peripheral blood lymphocyte (PBL) cells but not polymorphonuclear neutrophils (PMN) 
cells [61], indicating a pro-inflammation role of MSMP. MSMP was also found to 
stimulate p-ERK, which plays a central signaling role in cancer progression [62, 63]. Our 
results demonstrate that FO can lower MSMP levels, offering an additional explanation 
for the anti-inflammation action of n-3 FAs in prostate cancer. Taken together, FO and 
OA both suppress FA synthesis activity but only FO inhibits cell survival. Global 
proteomic studies and following validation demonstrated that FO modulates protein 
levels of SQSTM1, MSMP, and SCP2 in PCa cells, suggesting a possible longitudinal 
regulation by FO: inducing cytotoxicity after short treatment; suppressing inflammation 
pathways and inhibiting the glycolytic pathway in prolonged treatment. 
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Figure Legends 
Figure 1: Effects of FO and OA on PCa cell viability. A: MTT assay was measured 
24-hr after PC3 cells were treated by control (0.1% ethanol), 100 μM fish oil or 100 μM 
oleic acid (n=3). B: PC3 cells were seeded at 1000 cell/well in 6-well plates, treated with 
control (0.1% ethanol), 100 μM FO, or 100 μM OA, respectively. Cells grew for 
approximately one week until the colonies were visible. Cells were fixed by methanol 
and stained with crystal violet (n=3). C: PC3 cell images captured during colony 
formation. 
  
Figure 2: Effects of FO and OA on FASN activity in PC3 cells. Cells were seeded in 
24-well cluster plates, treated with vehicle (0.1% ethanol), 100 μM FO or 100 μM OA for 
3 days or 6 days. FASN activity was measured by 14C-acetate incorporation assay, in 
which the scintillation counts were normalized by cell counts in parallel treated wells 
(n=3). 
 
Figure 3: Principal component analysis (PCA). A: PCA analysis of 127 significantly 
changed proteins (ANOVA p≤0.05, q≤0.05, n=5) shows graphic distribution of 30 
samples (6 groups and 5 replicates in each) on axes of component 1 (F1) and 
component 2 (F2). B: By one minus Pearson Correlation, three major clusters were 
generated out of 73 proteins selected based on 127 proteins in (A) and has at least one 
significant change (t-test p≤0.05, n=5) in FO1/CN1 (fish oil vs. control, one-day), 
OA1/CN1 (oleic acid vs. control, one-day), FO6/CN6 (fish oil vs. control, six-day), or 
OA6/CN6 (oleic acid vs. control, six-day).  
  
Figure 4. Enzyme functions in glycolysis/gluconeogenesis and its relative pathways are 
changed. Differentially expressed glycolysis/gluconeogenesis proteins in cluster C (*: t-
test p≤0.05, n=5) 
 
Figure 5: MRM validation of expression changes of MSMP (A), SCP2 (B) in FO or OA 
group compared to control, with internal control RPL6 (C) and spiked-in external control 
chicken lysozyme (D) (n=6). 
 
Figure 6: Western Blot validation of expression changes of MSMP, SQSTM1 and 
autophagy marker LC3 I/II in FO or OA group. (A) SQSTM1 and -actin; (B) Bar 
graph quantification of (A), n=3; (C) SQSTM-1 mRNA level by RT-PCR (GUSB mRNA 
serves as internal standard), n=5; (D) Western blot of LC3 I/II from cells treated with 
different FAs in the presence of 8 μM CQ for 1 day; (E) Bar graph quantification of (D), 
n=3; (F) secreted MSMP in medium; (G) Bar graph quantification of (F), n=3. 
  
 
 
 
